New drug combo targets advanced cancers in Mid-Stage trial
NCT ID NCT07130383
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two experimental drugs, MHB036C and MHB039A, given together to people with advanced breast cancer or other advanced solid tumors that have spread. The goal is to see if the combination is safe and can shrink tumors. About 210 adults aged 18 to 75 with measurable tumors and adequate organ function will participate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 210 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2025
- Expected to finish
-
Aug 2031
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Voluntarily agrees to participate in the study and signs the informed consent form. 2. Age ≥ 18 and ≤75 years, no restriction on gender. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 4. Estimated life expectancy ≥ 3 months. 5. Histologically or cytologically confirmed locally advanced or metastatic advanced solid tumors. 6. At least one measurable lesion per RECIST v1.1 criteria. 7. Adequate bone marrow reserve and organ function. 8. Eligible participants of childbearing potential (males and females) must agree to take highly reliable contraceptive measures with their partners during the study and within at least 12 weeks after the last dose. \- Exclusion Criteria: 1. History of ≥2 primary malignancies within 5 years prior to informed consent. 2. Received anti-tumor treatment within 4 weeks or within the 5 half-lives of the previous treatment (whichever is shorter) before dosing. 3. Medication of other unmarketed investigational drugs or therapies within 4 weeks before dosing. 4. Undergone major organ surgery (excluding biopsy) or significant trauma within 4 weeks before dosing or requiring elective surgery during the study. 5. Vaccinated with attenuated live vaccines within 4 weeks before dosing. 6. Treated with with systemic corticosteroids within 14 days before dosing. 7. Central nervous system metastasis. 8. Uncontrolled third-space effusion. 9. Serious cardiovascular or cerebrovascular diseases. 10. Severe lung disease affecting pulmonary function. 11. Active infection requiring systemic therapy. 12. Known hypersensitivity or delayed allergic reaction to the investigational product or its components. 13. Drug abuse or other medical/psychiatric condition that may interfere with study participation or results. 14. Known alcohol or drug dependence. 15. Pregnant or breastfeeding women, or individuals planning to conceive.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Advanced breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 201419, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo outsmart breast cancer that resists current therapy?
- Can a new tracer make tumors light up on scans?
- Can fasting and exercise beat cancer fatigue?
- CBD as a calming agent for Scan-Related anxiety in advanced breast cancer?
- Can a new pill tame advanced breast cancer?
- Can a Two-Step drug combo outsmart advanced HER2-Positive breast cancer?